Editas Medicine Inc

Fermé

SecteurSoins de santé

3.5 6.06

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.12

Max

3.4699999999999998

Chiffres clés

By Trading Economics

Revenu

-19M

-25M

Ventes

-22M

2.8M

BPA

-0.26

Marge bénéficiaire

-882.444

Employés

87

EBITDA

-18M

-23M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+119.51% upside

Dividendes

By Acuity

Prochains Résultats

10 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

173M

467M

Ouverture précédente

-2.56

Clôture précédente

3.5

Sentiment de l'Actualité

By Acuity

50%

50%

123 / 342 Classement par Healthcare

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juil. 2026, 23:52 UTC

News
Correlated Moves
Social Media

Meta Platforms Inc. shares fell in after-market trading amid a broader tech market downturn, despite earlier gains on plans for a cloud computing business.

1 juil. 2026, 23:51 UTC

Social Media
News
Correlated Moves
ETF Constituents

Invesco QQQ Trust trading lower after Nasdaq 100 decline, reflecting a market shift away from technology stocks. Notable trades occurred at $737.25.

1 juil. 2026, 23:36 UTC

Correlated Moves
News

Ethereum is trading higher, buoyed by Bitcoin's recent gains. Earlier in the session, Ethereum peaked before pulling back slightly but has since regained ground.

1 juil. 2026, 23:36 UTC

News
Social Media

AMD shares are higher in after-market hours following a $36 million equity award announcement for CEO Lisa T. Su and positive discussions at HPE Discover 2026.

1 juil. 2026, 23:36 UTC

News
Correlated Moves

Ethereum is trading higher, supported by Bitcoin's recent strong move. It pulled back slightly from earlier session highs but remains above Tuesday's close.

1 juil. 2026, 23:31 UTC

News

United States Oil Fund LP advances in after-market trading, despite lower oil prices and mixed global equity performance. No specific news identified for the move.

1 juil. 2026, 23:16 UTC

Correlated Moves
News

Qualcomm Inc. shares rose in after-market trading, reflecting a modest gain since Wednesday's close, amid KLA Corp's price increase and recent index removals.

1 juil. 2026, 23:06 UTC

News
ETF Constituents

Vanguard Growth ETF declines in after-market trading, reversing earlier gains. Broader market faces pressure from economic data and geopolitical tensions.

1 juil. 2026, 23:06 UTC

Social Media
News
ETF Constituents

The SPDR Dow Jones Industrial Average ETF Trust declined slightly in after-market hours, reflecting broader market trends and mixed investor sentiment.

1 juil. 2026, 23:06 UTC

News
Correlated Moves
ETF Constituents

The Nasdaq 100 Index shows slight gains in after-market hours, while the Vanguard Information Technology ETF remains roughly flat amid stable trading conditions.

1 juil. 2026, 22:51 UTC

News

Buy rating upgrade from Guggenheim boosts CHKP in after-market.

1 juil. 2026, 20:07 UTC

News
Social Media

American Airlines shares rise as Bernstein raises price target to $23. FAA's approval for supersonic flights may boost investor sentiment.

1 juil. 2026, 20:07 UTC

News

The Nikkei 225 Index is lower in after-market hours, reflecting significant volatility amid broader market sell-offs in technology stocks. No specific news was identified.

1 juil. 2026, 20:05 UTC

Correlated Moves
ETF Constituents
News

The iShares MSCI United Kingdom ETF is lower today amid reduced Bank of England rate hike expectations and a decline in the U.K. Manufacturing PMI.

1 juil. 2026, 20:04 UTC

Macro News
Macro Event
ETF Constituents
News

The Communication Services Select Sector SPDR Fund is rising amid a broader market rally, driven by strong gains in Meta Platforms and the overall sector.

1 juil. 2026, 20:04 UTC

Social Media
News
Macro Event
ETF Constituents

VanEck Gold Miners ETF declines as broader market dynamics weigh on investor sentiment, despite a rise in spot gold prices to $4,085 an ounce.

1 juil. 2026, 20:04 UTC

Social Media
News
ETF Constituents

iShares China Large-Cap ETF gains amid positive sentiment following the China foreign minister's remarks on U.S. relations and strong performance from constituent stocks.

1 juil. 2026, 20:04 UTC

Correlated Moves
News
Event
Macro Event
Social Media

iShares 20+ Year Treasury Bond ETF declines amid rising Treasury yields and comments from Federal Reserve Chair Kevin Warsh on high prices. The ETF went ex-dividend today at $0.31803.

1 juil. 2026, 20:03 UTC

News

Piper Sandler raised Illumina's price target to $200, contributing to shares trading higher today. The company also expanded its board with a new appointment.

1 juil. 2026, 20:03 UTC

Macro Event
News

Willis Towers Watson PLC launched its expanded CyMax Facility for cyber insurance aimed at SMEs in the EMEA region, boosting shares during Wednesday's session.

1 juil. 2026, 20:03 UTC

News
Correlated Moves

NXP Semiconductors NV's stock is lower amid negative assessment from StockStory, citing revenue concerns and lagging growth compared to industry averages.

1 juil. 2026, 20:03 UTC

Social Media
News

Adobe Inc. is trading higher during Wednesday's session, with analysts suggesting potential for recovery amid ongoing interest in the software sector despite recent challenges.

1 juil. 2026, 20:03 UTC

Social Media
News

Microsoft's stock rises on a five-year partnership with Haleon to enhance AI capabilities. A Jefferies survey shows Azure gaining traction over AWS.

1 juil. 2026, 20:02 UTC

News

Align Technology Inc. shares are higher as the company addresses an antitrust investigation and announces plans for its second-quarter 2026 financial results.

1 juil. 2026, 20:02 UTC

Macro Event
Social Media
News

Automatic Data Processing's stock rose following the ADP National Employment Report, which showed a 98,000 increase in private sector jobs for June.

1 juil. 2026, 20:02 UTC

Correlated Moves
News

Analog Devices Inc. shares are lower today, impacted by a significant decline in the semiconductor sub-sector and broader market volatility.

1 juil. 2026, 19:56 UTC

Correlated Moves
News

The U.S. dollar is near two-week lows, impacting the Invesco Currencyshares Japanese Yen Trust, which is trading roughly flat amid ongoing geopolitical tensions.

1 juil. 2026, 19:56 UTC

Macro Event
Correlated Moves
ETF Constituents
Macro News
News

Energy Select Sector SPDR Fund declines amid broader energy sector downturn and falling crude oil prices. ExxonMobil and Schlumberger contribute to negative performance.

1 juil. 2026, 19:51 UTC

Social Media
News
Macro Event

Cognizant Technology Solutions shares rise following the launch of Cognizant Neuro AI Trust, despite HSBC lowering its price target to $68 from $80.

1 juil. 2026, 19:47 UTC

Correlated Moves
Social Media
News

Alphabet Inc shares are higher as the company surpasses its $1 billion investment target in Africa, despite mixed social media sentiment regarding recent legal challenges.

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

119.51% hausse

Prévisions sur 12 Mois

Moyen 7.2 USD  119.51%

Haut 15 USD

Bas 4 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

5

Achat

1

Maintien

1

Vente

Sentiment

By Acuity

123 / 342Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat